Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) reported positive interim results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422. Shares of the biopharmaceutical climbed $1.93 to $16.14.